Dicycloplatin (DCP) is a novel platinum analog that demonstrates significant antitumor activity against a variety of human cancer cell lines with IC50 of 25-30 nM; has better solubility and stability than both cisplatin and carboplatin
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.